BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 19887476)

  • 1. A multimarker prognostic assay for primary cutaneous melanoma.
    Kashani-Sabet M; Venna S; Nosrati M; Rangel J; Sucker A; Egberts F; Baehner FL; Simko J; Leong SP; Haqq C; Hauschild A; Schadendorf D; Miller JR; Sagebiel RW
    Clin Cancer Res; 2009 Nov; 15(22):6987-92. PubMed ID: 19887476
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of nuclear receptor coactivator-3 overexpression in primary cutaneous melanoma.
    Rangel J; Torabian S; Shaikh L; Nosrati M; Baehner FL; Haqq C; Leong SP; Miller JR; Sagebiel RW; Kashani-Sabet M
    J Clin Oncol; 2006 Oct; 24(28):4565-9. PubMed ID: 17008696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective Validation of Molecular Prognostic Markers in Cutaneous Melanoma: A Correlative Analysis of E1690.
    Kashani-Sabet M; Nosrati M; Miller JR; Sagebiel RW; Leong SPL; Lesniak A; Tong S; Lee SJ; Kirkwood JM
    Clin Cancer Res; 2017 Nov; 23(22):6888-6892. PubMed ID: 28790109
    [No Abstract]   [Full Text] [Related]  

  • 4. Osteopontin as a molecular prognostic marker for melanoma.
    Rangel J; Nosrati M; Torabian S; Shaikh L; Leong SP; Haqq C; Miller JR; Sagebiel RW; Kashani-Sabet M
    Cancer; 2008 Jan; 112(1):144-50. PubMed ID: 18023025
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel role for RGS1 in melanoma progression.
    Rangel J; Nosrati M; Leong SP; Haqq C; Miller JR; Sagebiel RW; Kashani-Sabet M
    Am J Surg Pathol; 2008 Aug; 32(8):1207-12. PubMed ID: 18580492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prognostic significance of non-sentinel lymph node metastasis in cutaneous and acral melanoma patients-A multicenter retrospective study.
    Sun W; Xu Y; Yang J; Liao Z; Li T; Huang K; Patel P; Yan W; Chen Y
    Cancer Commun (Lond); 2020 Nov; 40(11):586-597. PubMed ID: 33025763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Triple-marker PCR assay of sentinel lymph node as a prognostic factor in melanoma.
    Ito T; Wada M; Nagae K; Nakano-Nakamura M; Nakahara T; Hagihara A; Furue M; Uchi H
    J Eur Acad Dermatol Venereol; 2015 May; 29(5):912-8. PubMed ID: 25199412
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of galectin-3 in primary cutaneous melanoma.
    Buljan M; Šitum M; Tomas D; Milošević M; Krušlin B
    J Eur Acad Dermatol Venereol; 2011 Oct; 25(10):1174-81. PubMed ID: 21175876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sentinel lymph node micrometastasis and other histologic factors that predict outcome in patients with thicker melanomas.
    Cherpelis BS; Haddad F; Messina J; Cantor AB; Fitzmorris K; Reintgen DS; Fenske NA; Glass LF
    J Am Acad Dermatol; 2001 May; 44(5):762-6. PubMed ID: 11312421
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic implications of anatomic location of primary cutaneous melanoma of 1 mm or thicker.
    Callender GG; Egger ME; Burton AL; Scoggins CR; Ross MI; Stromberg AJ; Hagendoorn L; Martin RC; McMasters KM
    Am J Surg; 2011 Dec; 202(6):659-64; discussion 664-5. PubMed ID: 22137134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The sentinel lymph node status is an important factor for predicting clinical outcome in patients with Stage I or II cutaneous melanoma.
    Statius Muller MG; van Leeuwen PA; de Lange-De Klerk ES; van Diest PJ; Pijpers R; Ferwerda CC; Vuylsteke RJ; Meijer S
    Cancer; 2001 Jun; 91(12):2401-8. PubMed ID: 11413531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sentinel lymph node biopsy in melanoma: a micromorphometric study relating to prognosis and completion lymph node dissection.
    Debarbieux S; Duru G; Dalle S; Béatrix O; Balme B; Thomas L
    Br J Dermatol; 2007 Jul; 157(1):58-67. PubMed ID: 17501957
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lymphatic invasion identified by monoclonal antibody D2-40, younger age, and ulceration: predictors of sentinel lymph node involvement in primary cutaneous melanoma.
    Niakosari F; Kahn HJ; McCready D; Ghazarian D; Rotstein LE; Marks A; Kiss A; From L
    Arch Dermatol; 2008 Apr; 144(4):462-7. PubMed ID: 18427039
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A seven-marker signature and clinical outcome in malignant melanoma: a large-scale tissue-microarray study with two independent patient cohorts.
    Meyer S; Fuchs TJ; Bosserhoff AK; Hofstädter F; Pauer A; Roth V; Buhmann JM; Moll I; Anagnostou N; Brandner JM; Ikenberg K; Moch H; Landthaler M; Vogt T; Wild PJ
    PLoS One; 2012; 7(6):e38222. PubMed ID: 22685558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of occult melanoma cells in paraffin-embedded histologically negative sentinel lymph nodes using a reverse transcriptase polymerase chain reaction assay.
    Palmieri G; Ascierto PA; Cossu A; Mozzillo N; Motti ML; Satriano SM; Botti G; Caracò C; Celentano E; Satriano RA; Lissia A; Tanda F; Pirastu M; Castello G;
    J Clin Oncol; 2001 Mar; 19(5):1437-43. PubMed ID: 11230489
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic factors associated with sentinel lymph node positivity and effect of sentinel status on survival: an analysis of 1049 patients with cutaneous melanoma.
    Kunte C; Geimer T; Baumert J; Konz B; Volkenandt M; Flaig M; Ruzicka T; Berking C; Schmid-Wendtner MH
    Melanoma Res; 2010 Aug; 20(4):330-7. PubMed ID: 20526218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumour lymphangiogenesis is a possible predictor of sentinel lymph node status in cutaneous melanoma: a case-control study.
    Massi D; Puig S; Franchi A; Malvehy J; Vidal-Sicart S; González-Cao M; Baroni G; Ketabchi S; Palou J; Santucci M
    J Clin Pathol; 2006 Feb; 59(2):166-73. PubMed ID: 16443733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lymphatic invasion predicts sentinel lymph node metastasis and adverse outcome in primary cutaneous melanoma.
    Moy AP; Mochel MC; Muzikansky A; Duncan LM; Kraft S
    J Cutan Pathol; 2017 Sep; 44(9):734-739. PubMed ID: 28555886
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular and biochemical testing in stage III melanoma: multimarker reverse transcriptase-polymerase chain reaction assay of lymph fluid after lymph node dissection and preoperative serum lactate dehydrogenase level.
    Nowecki ZI; Rutkowski P; Kulik J; Siedlecki JA; Ruka W
    Br J Dermatol; 2008 Sep; 159(3):597-605. PubMed ID: 18616789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of metallothionein-overexpression with sentinel lymph node biopsy as prognostic factors in melanoma.
    Weinlich G; Topar G; Eisendle K; Fritsch PO; Zelger B
    J Eur Acad Dermatol Venereol; 2007 May; 21(5):669-77. PubMed ID: 17447982
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.